Personalized Medicine Biomarkers Market Report 2026

Personalized Medicine Biomarkers Market Overview

• Personalized Medicine Biomarkers market size has reached to $26.73 billion in 2025 • Expected to grow to $58.8 billion in 2030 at a compound annual growth rate (CAGR) of 17% • Growth Driver: Rising Prevalence Of Chronic Diseases Driving Growth Of The Market Due To Increasing Need For Targeted Treatments And Precision Diagnostics • Market Trend: Regulatory Approvals Enhance Advancements In Personalized Medicine • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Personalized Medicine Biomarkers Market?

Personalized medicine biomarkers are specific biological indicators that tailor medical treatments to individual patients based on their unique genetic, molecular, or physiological characteristics. These biomarkers can help predict how a patient will respond to a particular drug, enabling doctors to choose the most effective and safest treatment options. The main types of biomarkers in personalized medicine are genomic, proteomic, metabolic, and others. Genomic biomarkers are specific genes or genetic mutations that help in understanding how diseases develop and progress in individuals. It is used for various disease indications, including oncology, neurology, diabetes, autoimmune diseases, cardiology, and others, for various applications, including early detection or screening, diagnosis, treatment selection, and monitoring. And it caters to various end users, including hospitals and clinics, pharmaceutical and biotechnology companies, diagnostic labs, and others.

What Is The Personalized Medicine Biomarkers Market Growth Forecast?

The personalized medicine biomarkers market size is expected to see rapid growth in the next few years. It will grow to $58.8 billion in 2030 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to expansion of personalized therapeutics, rising demand for early disease detection, growth in pharmacogenomics, increasing investment in biomarker discovery, wider adoption across non-oncology indications. Major trends in the forecast period include rising adoption of precision treatment approaches, increasing use of biomarkers in oncology care, growing integration of companion diagnostics, expansion of predictive and prognostic biomarkers, higher focus on treatment response monitoring.

Global Personalized Medicine Biomarkers Market Segmentation

1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types 2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications 3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring 4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users Subsegments: 1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers 2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers 3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers 4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers

What Is The Driver Of The Personalized Medicine Biomarkers Market?

The growing prevalence of chronic diseases is expected to propel the growth of the personalized medicine biomarkers market going forward. Chronic diseases are long-term medical conditions that progress slowly and persist for a year or more, requiring ongoing medical attention or limiting daily activities. The growing prevalence of chronic diseases is due to unhealthy lifestyle choices, inferior diets, lack of physical activity, and high levels of stress. Personalized medicine biomarkers help tailor treatments for chronic diseases by identifying effective therapies, predicting disease progression, and minimizing adverse effects based on individual genetic and molecular profiles. For instance, in February 2024, according to the World Health Organization (WHO), a Switzerland-based health authority, by 2050, the number of new cancer cases is expected to surpass 35 million, representing a 77% increase from the estimated 20 million cases in 2022. Therefore, the growing prevalence of chronic diseases is driving the growth of the personalized medicine biomarkers industry.

Key Players In The Global Personalized Medicine Biomarkers Market

Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

Global Personalized Medicine Biomarkers Market Trends and Insights

Major companies operating in the personalized medicine biomarkers market are focusing on obtaining regulatory approvals such as companion diagnostic approval to enhance precision oncology by rapidly matching patients to targeted therapies. Companion diagnostic approval refers to the regulatory authorization granted by a health authority (such as the FDA) for a diagnostic test that is specifically designed to identify patients who are most likely to benefit from a particular therapeutic product or are at increased risk of adverse reactions. For instance, in August 2024, Illumina, Inc., a US-based biotechnology company, received the Food and Drug Administration (FDA) approval for its cancer biomarker test and two companion diagnostics. The test uses next-generation sequencing (NGS) technology to identify genetic mutations in cancer cells, enabling clinicians to select the most suitable treatments based on individual biomarkers. This approval marks a significant advancement in precision oncology, aiming to improve the speed and accuracy of treatment selection for cancer patients, ultimately enhancing personalized care.

What Are Latest Mergers And Acquisitions In The Personalized Medicine Biomarkers Market?

In February 2025, Renovaro Inc., a US-based biotechnology company, merged with BioSymetrics Inc. to enhance AI-driven biomarker discovery and precision medicine. The merger aims to enhance drug development and create more personalized treatment strategies, addressing complex diseases through innovative, data-driven approaches. BioSymetrics Inc. is a Canada-based phenomics-driven drug discovery company integrating clinical and experimental data using machine learning to advance precision medicine.

Regional Insights

North America was the largest region in the personalized medicine biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Personalized Medicine Biomarkers Market?

The personalized medicine biomarkers market consists of sales of biomarker-based diagnostic kits, reagents, testing platforms, epigenetic biomarkers, companion diagnostics, predictive biomarkers, prognostic biomarkers, and multi-omics biomarkers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Personalized Medicine Biomarkers Market Report 2026?

The personalized medicine biomarkers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the personalized medicine biomarkers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.